Point72 Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,340,300
| Closed | -$7.83M | – | 2621 |
|
|
2022
Q4 | $7.83M | Buy |
1,340,300
+1,069,700
| +395% | +$5.63M | 0.03% | 627 |
|
|
2022
Q3 | $1.81M | Buy |
+270,600
| New | +$1.64M | 0.01% | 943 |
|
|
2021
Q1 | – | Sell |
-893,741
| Closed | -$11.3M | – | 1251 |
|
|
2020
Q4 | $11.3M | Buy |
893,741
+118,741
| +15% | +$1.35M | 0.06% | 414 |
|
|
2020
Q3 | $7.61M | Buy |
775,000
+590,862
| +321% | +$5.82M | 0.04% | 470 |
|
|
2020
Q2 | $1.83M | Buy |
+184,138
| New | +$1.77M | 0.01% | 606 |
|
|
2017
Q4 | – | Sell |
-57,134
| Closed | -$843K | – | 1144 |
|
|
2017
Q3 | $843K | Buy |
+57,134
| New | +$829K | ﹤0.01% | 761 |
|
|
2016
Q4 | – | Sell |
-414,479
| Closed | -$4.19M | – | 874 |
|
|
2016
Q3 | $4.19M | Buy |
414,479
+10,000
| +2% | +$109K | 0.03% | 450 |
|
|
2016
Q2 | $4.54M | Buy |
404,479
+54,107
| +15% | +$689K | 0.03% | 444 |
|
|
2016
Q1 | $4.79M | Buy |
+350,372
| New | +$5.04M | 0.04% | 436 |
|
|
2015
Q3 | – | Sell |
-555,000
| Closed | -$8.26M | – | 933 |
|
|
2015
Q2 | $8.26M | Buy |
555,000
+29,800
| +6% | +$454K | 0.06% | 357 |
|
|
2015
Q1 | $7.95M | Buy |
525,200
+25,200
| +5% | +$352K | 0.05% | 368 |
|
|
2014
Q4 | $6.66M | Sell |
500,000
-34,200
| -6% | -$442K | 0.05% | 393 |
|
|
2014
Q3 | $6.74M | Buy |
+534,200
| New | +$5.18M | 0.05% | 346 |
|
Point72 Asset Management's CNCE Position: Q1 2023 in Review
Point72 Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,340,300 shares — an estimated $7.83M sold.
Point72 Asset Management first reported a position in CNCE in Q3 2014 and held it in 13 quarters. The position peaked at $11.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Point72 Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Point72 Asset Management sold 1,340,300 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $7.83M.
- Point72 Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2014 and held it in 13 quarters.
- Point72 Asset Management's Concert Pharmaceuticals, Inc. position peaked at $11.3M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Point72 Asset Management's 13F filing for Q1 2023, filed 15 May 2023.